Insulin resistance in pheochromocytoma improves more by surgical rather than by medical treatment

Evanthia Diamanti-Kandarakis¹, Evangelia Zapanti¹, Maria-Helen Peridis², Panayiotis Ntavos¹, George Mastorakos²

¹First Department of Internal Medicine, Endocrine and Metabolic Unit, Laikon General Hospital, Athens University, School of Medicine, Athens, Greece and ²Second Department of Obstetrics and Gynecology, Endocrine Unit, Aretaieion Hospital, Athens University, School of Medicine, Athens, Greece

ABSTRACT

Pheochromocytoma, a neuroendocrine tumor, is often associated with hyperglycemia. To investigate the underlying pathogenetic mechanisms, five patients (3 women and 2 men, aged 49±2.5, mean±SD) with benign adrenal pheochromocytoma were studied with an oral glucose tolerance test (OGTT) and the euglycaemic clamp technique. They were studied preoperatively without taking any medication (stage I), after taking an alpha adrenergic receptor blocking agent (stage II), after taking both an alpha and a beta adrenergic receptor blocking agent (stage III), and after surgical removal of the tumor (stage IV). Before any treatment, fasting blood glucose levels and glucose levels during the OGTT were pathologic in all patients. In all patients, mean glucose levels of the OGTTs performed at the three preoperative stages of the study were significantly higher than those of the OGTT performed postoperatively (ANOVA, α<0.05). Insulin levels during the OGTTs performed preoperatively peaked at 90 min while postoperatively they peaked at 60 min. No statistically significant difference was found among mean insulin levels during the OGTTs performed at all stages of the study. The clamp-based insulin sensitivity index (SI) improved progressively from stage I to IV of the study (ANOVA, α<0.05) (SIs of stages I, II, III, and IV were, respectively, 3.23±0.9 (mean±SE), 3.79±0.7, 4.67±0.3, 6.38±1 (10⁴ dl/kg/min per μU/ml)). In conclusion, the pheochromocytoma-associated metabolic alterations of glucose homeostasis improved substantially only after removal of the tumor. The administration of alpha and beta adrenergic receptor blocking agents resulted in a slight but statistically significant improvement in glucose utilization whereas it completely normalized the cardiovascular manifestations of the disease. Thus, it is possible that either the dose of the adrenergic receptor blocking agent needed to control cardiovascular manifestations of pheochromocytoma is different than that needed for glucose metabolism normalization, or that other pheochromocytoma-associated factors may influence directly and/or indirectly carbohydrate homeostasis.

Key words: pheochromocytoma, insulin resistance, euglycaemic clamp

Address correspondence and requests for reprints to:
Dr. George Mastorakos, 3 Neofytou Vamva St, 10674, Athens, Greece, mail: mastorak@mail.kapatel.gr
Received 03-11-02, Revised 20-12-02, Accepted 27-12-02
INTRODUCTION

Catecholamines can exert their effects on carbohydrate metabolism directly, through stimulation of adrenoreceptors and indirectly, mainly through modulation of pancreatic insulin and glucagon release. Both direct and indirect effects result in a prompt rise in plasma glucose. Stimulation of beta adrenoreceptors in the liver leads to a transient increase in glucose production by the liver via enhanced glycogenolysis and gluconeogenesis. The indirect actions of catecholamines on glucose production—which are quantitatively more important—are exerted via inhibition of insulin secretion by the pancreas (alpha-stimulation).

Another major effect of catecholamines on carbohydrate metabolism is the inhibition of skeletal muscle glucose uptake. Epinephrine interferes with carbohydrate metabolism primarily by decreasing exogenous glucose uptake rather than by increasing endogenous glucose production. Studies in humans have shown that while epinephrine stimulates hepatic glucose output and inhibits glucose uptake, norepinephrine stimulates transiently glucose output and has no effect on glucose uptake.

The mechanisms underlying the catecholamine-induced glucose intolerance have not, however, been fully investigated in pheochromocytoma. In an effort to elucidate the mechanisms via which pheochromocytoma-associated hypercatecholaminemia affects carbohydrate metabolism, we examined glucose tolerance in five patients with pheochromocytoma, preoperatively without and with pharmacological beta and/or alpha adrenergic receptor blockade, as well as after surgical removal of the tumor.

PATIENTS AND METHODS

Patients

Five patients (3 women and 2 men, aged 49±2.5, mean±SD) with pheochromocytoma were studied before and after medical and surgical treatment. Pheochromocytoma was suspected on the basis of clinical signs and symptoms and confirmed by elevated plasma catecholamines, urinary metanephrine and VMA levels (Table 1) as well as by imaging studies (computerized tomography and [131]I meta-iodo-benzyl-guanidine -MIBG- scan).

Protocol

The patients were studied while hospitalized. The study protocol comprised three preoperative stages and one postoperative. At each stage, an oral glucose tolerance test (OGTT) and a euglycaemic clamp study were performed with a three-day interval. Hypertensive crises when occurring (systolic and diastolic blood pressure exceeding 170 and 95 mmHg, respectively) were treated with nifedipine, a calcium channel blocker (Bayer, Greece). All patients were informed and gave their consent for the study.

Preoperatively:

Stage 1: Patients were studied before receiving any medication.

Stage 2: Patients were studied following a four-week treatment with an alpha-adrenergic receptor blocking agent (10 mg phenoxybenzamine t.i.d.). Alpha-adrenergic receptor blockade was confirmed clinically by postural hypotension and cardiac rate >90 pulses/min.

Stage 3: Patients were studied following an additional two-week treatment with both an alpha and a beta adrenergic receptor blocking agent (respectively, 10 mg phenoxybenzamine t.i.d. and propranolol 10-40 mg t.i.d.).

Postoperatively:

Stage 4: Patients were studied three months after surgical removal of the tumor.

Methods

Oral glucose tolerance test (OGTT): After a 10-h overnight fast, a Teflon cannula was inserted in an antecubital vein under local anesthesia with lignocaine 1%, connected with a 3-way catheter (Abbott-Hellas, Athens, Greece) and kept patent by intermittent infusion with saline 0.9%. The patients sat quietly for 30 min; then the first two blood samples were drawn at 7:30 and at 8:00 am. 75g glucose were subsequently administered per os, and blood sampling followed at 30-min intervals until 10:00 am.

Insulin clamp studies: Tissue sensitivity to insulin was determined by the euglycaemic clamp technique as previously described. An iv catheter was inserted retrogradely into a dorsal vein on the left arm kept warm via a heated blanket for intermittent sampling of arterialized venous blood. A second catheter was
inserted into an antecubital vein in the controlateral arm for administration of glucose and insulin infusions. After collection of three baseline blood samples over 30 min, a primed continuous infusion of crystalline human insulin (NOVO NORDISC HELLAS Ltd., Athens, Greece) was started at a constant rate (40 mU/m² body surface area/min) via an infusion pump for 180 min to increase plasma insulin levels to approximately 574.4 µmol/l while maintaining plasma glucose at the basal level (4.44-4.94 mmol/l) by sampling every 5 min. Plasma glucose was clamped at this level by periodically adjusting a variable infusion of a 35% dextrose via an Abbott Lifecare infusion pump (Abbott Laboratories, Inc., Chicago, IL). Insulin levels were measured in blood samples withdrawn at 20 min intervals.

**Hormone assays**

At each sampling time-point, 10 ml free-flowing blood was withdrawn after discarding the first 2ml, in lithium-heparin tubes and centrifuged immediately at 4°C. Plasma was immediately refrigerated at -70°C for assay of catecholamines and -20°C for assay of insulin. Blood glucose was assayed immediately.

**Calculations**

**Clamp-based index of insulin sensitivity (SI):** The steady-state period of the insulin clamp was defined as the final 30-min period (i.e. 150-180 min) during which the coefficient of variation for blood glucose, plasma insulin and glucose infusion rate (GIR) was less than 7% and the correlation of each variable with time was not significant. Mean value was defined as the GIR corrected for the glucose added or removed from the glucose space (space correction) as previously described. The glucose clamp-derived index of insulin sensitivity (SIclamp) was calculated as follows: 

\[ SI_{clamp} = \frac{GIR_o}{G_a} \Delta I_o \]

where GIRo is the steady-state glucose infusion rate (mg/kg per min), Ga is the steady-state blood glucose concentration (mg/dl) and ΔIo is the difference between steady-state and basal insulin concentration (mU/ml)6.

**Statistical analysis**

To compare SI mean values as well as glucose and insulin mean values during OGTT among the four different stages of the study, the ANOVA method was employed. In order to apply the ANOVA method, normality of data was examined by quantile quantile plots, histograms, boxplots and Jarque-bera statistic which revealed that the distribution of the recorded data at each of the four stages of the study approximated the normal. Subsequently, ANOVA tables were applied and the t and f tests regarding comparisons of means between all possible pairs of glucose and insulin and among mean values of SI at each of the four stages of the study were calculated. The level of significance α was set at 0.05.

**RESULTS**

**Glucose response during OGTT (Figure 1)**

Before treatment, fasting blood glucose levels and OGTT were pathologic in all patients. Mean glucose levels of the OGTTs performed in all three preoperative stages of the study were significantly higher than those of the OGTT performed postoperatively in all patients (ANOVA, α<0.05) (Table 2). In addition, mean glucose levels of the OGTT performed preoperatively without any medication were significantly higher than those post alpha and beta blockade (ANOVA, α<0.05). Mean glucose levels of the OGTT post alpha blockade did not differ from those post alpha and beta blockade (ANOVA, α>0.05).

**Insulin response during OGTT (Figure 2)**

Insulin levels during the OGTTs performed preoperatively peaked at 90 min while postoperatively

---

Table 1. Mean value±sem of plasma catecholamines and urine VMA and metanephrine values.

<table>
<thead>
<tr>
<th>STAGES</th>
<th>EPINEPHRINE (0.07-0.6) nmol/l</th>
<th>NOREPINEPHRINE (0.48-1.91) nmol/l</th>
<th>VMA (&lt;50) µmol/24h</th>
<th>METANEPHRINE (&lt;5.46) µmol/24h</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>0.86±0.67</td>
<td>5.49±1.68</td>
<td>121±34.95</td>
<td>11.56±3.34</td>
</tr>
<tr>
<td>II</td>
<td>0.87±0.68</td>
<td>5.30±1.92</td>
<td>102±2.4</td>
<td>12.88±3.06</td>
</tr>
<tr>
<td>III</td>
<td>0.82±0.64</td>
<td>5.29±1.47</td>
<td>97±14.12</td>
<td>11.19±2.24</td>
</tr>
<tr>
<td>IV</td>
<td>0.27±0.09</td>
<td>7.34±1.42</td>
<td>18±5.7</td>
<td>1.07±0.23</td>
</tr>
</tbody>
</table>
they peaked at 60 min. No statistically significant difference was found among mean insulin levels of the OGTTs performed at all stages of the study (Table 3).

**Euglycaemic clamp studies**

Tissue sensitivity to insulin action as assessed by the euglycaemic clamp technique improved after each stage. The mean of the clamp-based insulin sensitivity index (SI) improved progressively in a statistically significant manner from stage I to stage IV of the study (ANOVA, α=0.05) (Table 4) (Figure 3).

**Cardiovascular effects**

The administration of alpha and beta adrenergic receptor blocking agents resulted in complete normalization of the cardiovascular manifestations of the disease.

**DISCUSSION**

Catecholamines play an important role in carbohydrate metabolism. Their hyperglycaemic actions are exerted directly on the liver (transient increase of glu-

---

**Table 2.** Mean glucose values and their standard errors during the OGTTs estimated calculated by the ANOVA method, at the four stages of the study.

<table>
<thead>
<tr>
<th>Glucose (mmol/l)</th>
<th>stage I</th>
<th>stage II</th>
<th>stage III</th>
<th>stage IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>mean</td>
<td>11.19</td>
<td>10.32</td>
<td>9.12</td>
<td>5.97</td>
</tr>
<tr>
<td>SEM</td>
<td>0.82</td>
<td>0.57</td>
<td>0.39</td>
<td>0.16</td>
</tr>
</tbody>
</table>

---

**Table 3.** Mean insulin levels and their standard errors during the OGTTs estimated by the ANOVA method, at the four stages of the study.

<table>
<thead>
<tr>
<th>Insulin (μmol/l)</th>
<th>stage I</th>
<th>stage II</th>
<th>stage III</th>
<th>stage IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>mean</td>
<td>357.85</td>
<td>413.28</td>
<td>341.76</td>
<td>335.16</td>
</tr>
<tr>
<td>SEM</td>
<td>38.77</td>
<td>19.17</td>
<td>43.86</td>
<td>52.70</td>
</tr>
</tbody>
</table>

**Table 4.** Mean clamp-based indexes of insulin sensitivity (SI) and their standard errors in the four stages of the study.

<table>
<thead>
<tr>
<th>SI (10^4 dl/kg·min per μU/ml)</th>
<th>stage I</th>
<th>stage II</th>
<th>stage III</th>
<th>stage IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>mean</td>
<td>3.23</td>
<td>3.79</td>
<td>4.67</td>
<td>6.38</td>
</tr>
<tr>
<td>SEM</td>
<td>0.17</td>
<td>0.16</td>
<td>0.39</td>
<td>0.47</td>
</tr>
</tbody>
</table>
glucose output via beta receptor stimulation), and indirectly (inhibition of insulin secretion by the pancreas, via alpha receptor stimulation)\(^9,10\). Nevertheless, their main effect is inhibitory on glucose uptake by the muscles.

We found that mean glucose levels during OGTT were abnormally increased before any medical treatment and they did not improve preoperatively after four weeks of treatment with an alpha blocking agent. However, the later addition of a beta blocking agent resulted in a statistical improvement of the mean glucose levels of OGTT. After surgical removal of the tumor, normalization of mean glucose levels of OGTT was achieved. Treatment by an alpha with and without a beta blocking agent as well as surgical removal of the tumor did not result in a statistically significant change of mean insulin levels during OGTT. However, the secretory pattern of insulin secretion during OGTT changed after surgery since its peak showed a tendency to move from the 90th minute preoperatively to the 60th minute postoperatively. The lack of insulin modification after treatment with an alpha blocking agent has also been reported by others\(^11\).

The euglycaemic clamp technique demonstrated a slight but statistically significant improvement of tissue sensitivity to insulin action post alpha blockade. Interestingly, studies using the same technique have shown that alpha blockade alone is not sufficient to prevent the hyperglycaemic effect of epinephrine infusion in normal man\(^12\). It has been reported that the inhibitory effect of epinephrine on glucose uptake may be reversed by the beta adrenergic receptor blocking agent propanolol\(^13\). In our study, after the addition of a beta adrenergic receptor blocking agent, insulin sensitivity improved but euglycaemia was not achieved. In contrast, alpha- and beta-mediated cardiovascular effects (hypertension, tachycardia) normalized. This may indicate that the sensitivity of adrenoreceptors to stimulatory and/or inhibitory agents varies in different tissues. It has been shown that the adrenoreceptors in different tissues are not activated by the same level of catecholamines. In fact, the plasma adrenaline threshold for eliciting cardiovascular effects is different than that eliciting metabolic effects\(^12,14,15\). Therefore, the therapeutic result may depend on the dose and/or the threshold of efficiency of alpha and/or beta blocking agents or on the type of secreted catecholamines. The best score for insulin sensitivity was achieved only after surgical removal of the tumor.

The effects of other tumor-secreted peptides on carbohydrate metabolism should also be considered\(^9\) as an explanation for normalization of glucose homeostasis only after tumor removal. Adrenal medulla, besides catecholamines, secretes a series of peptides such as vasoactive intestinal peptide (VIP), substance P, parathyroid hormone (PTH), PTH related peptide, enkephalins, endorphins, interleukin-6, insulin-like growth factor 2, chromogranin A, calcitonin, calcitonin gene related peptide, corticotropin releasing hormone, atrial natriuretic peptide (ANP) and neuropeptide Y. Certain symptoms caused by these peptides, such as pyrexia (II6), polyuria (ANP) and flushing (VIP), cannot be blocked by alpha and beta adrenergic receptor blocking agents. Some of these peptides may have antagonistic effects on insulin action, e.g. VIP has a strong homology to glucagon and stimulates lipolysis and glycogenolysis. Dopamine is co-secreted with catecholamines and is rarely the only product of a pheochromocytoma. Dopamine exerts an inhibitory effect on insulin release but it was not measured in our patients. The fact, however, that all tumors showed a positive MIBG scan and all patients were hypertensive argues against the exclusive secretion of dopamine.

In conclusion, the euglycaemic clamp technique revealed that the use of adrenergic blocking agents improves insulin resistance to a certain degree but does not restore the metabolic hyperglycaemic impact of pheochromocytoma. An optimal score for insulin sensitivity is achieved only by the surgical removal of the tumor.

REFERENCES